PT-112 in mCRPC (Prostate Cancer)

We are doing this study to learn if a new study drug called PT-112 is a safe and effective treatment for metastatic, castrate-resistant prostate cancer. This study is one of the first times PT-112 is being tested in humans. The study drug has been shown to induce cell death in tumor cells, and shrink tumors in animal studies. This study will also teach us how long the study drug stays in your body after you receive it.

Metastatic, Castrate-Resistant Prostate Cancer (mCRPC)

Adults who:
- Are diagnosed with mCRPC
- Are currently taking an androgen deprivation therapy OR have had a bilateral orchiectomy
- Have previously received at least 3 prior therapies for mCRPC, including at least one next-generation anti-androgen therapy and at least one taxane-containing therapy

For more information about who can join this study, please contact the study team at catrin.davies@duke.edu.

If you choose to join this study, you will:
- Receive the study drug through a vein in your arm (IV) once every 2 weeks
- Have blood draws
- Have imaging tests (CT, MRI, and/or bone scan)